MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Fri Aug 12 00:00:00 GMT-05:00 2022
Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
Download
Thu Aug 11 00:00:00 GMT-05:00 2022
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download
Tue Aug 09 00:00:00 GMT-05:00 2022
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer
Download
Mon Aug 08 00:00:00 GMT-05:00 2022
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Download
Fri Aug 05 00:00:00 GMT-05:00 2022
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
Download
Mon Jul 25 00:00:00 GMT-05:00 2022
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
Download
Wed Jul 20 00:00:00 GMT-05:00 2022
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
Download
Tue Jul 19 00:00:00 GMT-05:00 2022
Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury Verdict in Seagen Patent Dispute
Download
Mon Jul 18 00:00:00 GMT-05:00 2022
U.S. Patent Office Issues Decision on Seagen’s Rehearing Request in Patent Dispute
Download